Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18069601 | 0.77 | ALDH1A1 (0.34) | LPOPTGS1SMN1; SMN2 | |
| SCHEMBL16248 | 0.77 | MAPK1 (0.47) | CRBNTK1DAOMAPK1 | |
| SCHEMBL21836662 | 0.77 | CRBN (0.38) | CRBNP2RY2DAO | |
| SCHEMBL16575631 | 0.77 | CRBN (0.38) | CRBNP2RY2DAO | |
| SCHEMBL6420314 | 0.76 | MAPK1 (0.46) | CRBNTK1DAOMAPK1 | |
| SCHEMBL7546901 | 0.75 | TK1 (0.42) | TK1MAPK1 | |
| SCHEMBL20998663 | 0.74 | CRBN (0.39) | CRBNDAOBRD4SMN1; SMN2MAPK1 | |
| SCHEMBL22571159 | 0.74 | ALDH1A1 (0.34) | TK1 | |
| SCHEMBL11723021 | 0.74 | SMN1; SMN2 (0.44) | TK1LPOSMN1; SMN2MAPK1 | |
| SCHEMBL7554990 | 0.72 | TK1 (0.47) | TK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632468-B1 | 5-IODO-4-THIO-2'-DEOXYURIDINE FOR USE AS A RADIOSENSITIZER IN RADIOTHERAPY | UNIV GDANSKI (PL) | 2023-12-13 | — | — | EP | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | CRBN 4591/4885TK1 29/4885P2RY2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.